礼来:Taltz与Zepbound联合疗法在实现皮肤完全清除及体重下降≥10%方面优于Taltz单药治疗,达到主要终点

美股速递
Feb 18

礼来公司宣布,其药物Taltz与Zepbound的联合治疗方案在临床试验中达到了主要终点,显示出相较于Taltz单药治疗的优越性。该联合疗法在实现患者皮肤完全清除以及体重下降不低于10%两个关键指标上均表现优异。

研究结果显示,Taltz与Zepbound的组合不仅显著提升了皮肤病的治疗效果,还带来了可观的体重管理效益。这一成果为相关疾病患者提供了新的治疗选择,凸显了联合疗法的潜在价值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10